Safe Group announces FDA 510(k) clearance for SpineUp's Frida solution
Safe Group announces FDA 510(k) clearance for SpineUp's Frida solution
Fleurieux-sur-l'Arbresle - France - June 5, 2025 at 6 p.m. Safe Group, a leading player in the field of medical devices for spine surgery, is pleased to announce that Frida, the innovative cervical plate developed by SpineUp, has received 510(k) clearance from the Food and Drug Administration (FDA). This clearance marks a crucial step in SpineUp's expansion into the North American market, and testifies to its ongoing commitment to providing cutting-edge medical solutions.
Frida is a new-generation cervical plate offering high adaptability with a multiplicity of plate and screw sizes. Thanks to this technology, healthcare professionals will be able to offer more personalized treatments, tailored to the specific needs of surgeons and their patients.
FDA 510(k) clearance is the result of several years of research and development. This certification attests to the safety and efficacy of the Frida solution, which complies with the FDA's strict standards and is due to be marketed by the end of the year.
« In view of the merger of Safe's subsidiaries with SpineUp, we are delighted that this authorization has been granted and that SpineUp has taken a major step forward, validating the company's commitment to innovation and improving patient care," says Victor Humberdot, Chairman of Safe Group.
'This new step heralds new business opportunities for SpineUp and its subsidiaries Safe Orthopaedics and Safe Medical, increased synergy and a stronger foothold in the U.S.' comments Philippe Laurito, President of SpineUp Inc.
About Safe Group
Safe Group is a French medical technology group that brings together Safe Orthopaedics, a pioneer in ready-to-use technologies for spine pathologies, and Safe Medical (formerly LCI Medical), a medical device subcontractor for orthopedic surgeries. The group employs approximately 100 people.Safe Orthopaedics develops and manufactures kits combining sterile implants and ready-to-use instruments, available at any time to the surgeon. These technologies are part of a minimally invasive approach aimed at reducing the risks of contamination and infection, in the interest of the patient and with a positive impact on hospitalization times and costs. Protected by 15 patent families, SteriSpineTM kits are CE marked and FDA approved. Safe Orthopaedics has subsidiaries in the United Kingdom, Germany, the United States.For more information: www.safeorthopaedics.com
Safe Medical produces implantable medical devices and ready-to-use instruments. It has an innovation center and two production sites in France and in Tunisia, offering numerous industrial services: industrialization, machining, finishing and sterile packaging.For more information: www.safemedical.fr
ContactsSAFE GROUP AELYON ADVISORSinvestors@safeorthopaedics.com safe@aelyonadvisors.fr
Attachment
Safe_PR_SpineUp_FDA
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Buzz Feed
10 hours ago
- Buzz Feed
Money-Saving Skills That Will Save You Thousands
In this challenging economy, I'm always looking for ways to save money. Whether it's taking on DIY projects or learning how to spend less, simply knowing a few valuable life skills can save you thousands of dollars in the long run. If you're looking for a few economical hacks, you're in the right place. In one Reddit thread (which you can see here), people shared the simple and inexpensive life skills that basically made them richer, and I'm honestly going to look into some of these for myself. Ahead, I've rounded up 18 of the best skills: "I learned how to cut my dog's hair during COVID, watching videos on YouTube." "Dog grooming costs a good $70 every 2 months or so over the lifetime of the animal. So my dog has an uglier haircut, but I save thousands over the course of its life."–EarlyAd3047 "Simple handyman jobs. Get some basic tools and look up YouTube videos to save you from hiring a tradesman." "Doing 20 to 30 minutes of exercise daily will save you thousands in health costs down the road." "Cooking. It's not that hard to follow a recipe to get some decent meals." –FailedMaster "Basic sewing. Buttons, turning up trousers. So many people throw something away because it doesn't fit properly or the buttons come off." "How to budget and track expenses. Knowing where your money goes can prevent surprise overdrafts and debt." "Flossing properly. No more cavities or bleeding gums." –Thin_Pitch_4515 "Downloading digital coupons at home before you go to the grocery store." "I am a tax accountant, and I'd suggest doing your own taxes. The key is understanding when you have a complex situation. Most people without businesses or rentals can just do them online." "Learning how to make your own coffee." "A shit coffee machine is less than $30, and it'll make you coffee for as long as you take care of it. A French press will run you half that, and an electric kettle will run you less than the other half of $30. Paying more than 30 cents for a cup of coffee is wild. Do it yourself and stop paying $5 a cup for it."–theBJbanditO "Basic car maintenance — oil change, tire rotation, replacing filters. Saves a ton over time." "How to Google. But I'm serious, though. Knowing how to format a word or a question is extremely important to learn if you want to find answers. Also, if you don't even know what question to ask, knowing how to find enough info to inform yourself to ask the right question is important too." "Learning how to shop — whether it's groceries or general goods." "Small things like being able to compare prices by looking at price per ounce or unit instead of total cost. Taking the time to look over sales ads. Using manufacturers' coupons. App discounts. The list goes on. So many people mindlessly shop and get into a routine, and they don't realize how much they could save if they tried to."–buckeyebob45 "Basic retirement planning. You can save yourself thousands or even hundreds of thousands with a basic understanding of investing for retirement." "Mastering the phrase, 'let me think about it and get back to you.' Saves money and regrets." "Cycling. It takes some effort to figure out how to cycle around a city that's primarily built for cars, but the economic side is so worth it." –OldCadillac "How to negotiate your salary, or more precisely, how it's okay to try and negotiate your salary. Seriously, you can learn the basics in less than two hours, and it will earn you hundreds, maybe thousands of dollars each year for the rest of your life if you apply it." "Learned to cut my own hair. I bought a $45 cutter 10 years ago, and haven't gone to a barber since. At less than $35 a pop every six weeks, I figure I've saved over $3,000." Do you have a money-saving life skill that belongs on this list? Let me know what it is in the comments!
Yahoo
12 hours ago
- Yahoo
GSK (GSK) Gains FDA Approval for Benlysta Autoinjector for Lupus Treatment
GSK plc (NYSE:GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA approval for a 200 mg/mL autoinjector of Benlysta (belimumab) for the treatment of active lupus nephritis (LN). The approval applies to children aged five years and above. A pharmacist looking at a prescription bottle of gastrointestinal drugs. Benlysta autoinjector is the first-of-its-kind treatment option for at-home administration. The drug is a B-lymphocyte stimulator (BLyS)-specific inhibiting monoclonal antibody. It works by binding to soluble BLyS, which inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. It does not bind B cells directly. The 200 mg/mL autoinjector was previously approved for pediatric patients with active systemic lupus erythematosus (SLE) in 2024. Benlysta was the first and only approved biologic for both SLE and lupus nephritis in over 50 years, including for the pediatric population. The autoinjector will be available for patients and their caregivers immediately. GSK plc (NYSE:GSK) is a UK-based global biopharmaceutical company. It researches, develops, and sells medicines and vaccines for infectious diseases, HIV, respiratory conditions, cancer, and immune-related disorders. Its key products include Shingrix (shingles vaccine), Nucala (asthma), and HIV treatments through its ViiV Healthcare joint venture. While we acknowledge the potential of GSK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 hours ago
- Yahoo
Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines
Next phase builds on 34+ years of serving the needs of US patients and healthcare providers COLUMBUS, Ohio, June 28, 2025 /PRNewswire/ -- In its ongoing mission to help meet America's growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA today announces it will invest $1 billion by 2030 to further expand its US manufacturing and R&D capabilities. This new phase of investment -- America Leans on Hikma: Quality Medicines Manufactured in the USA – will further expand Hikma's well-established domestic capabilities to develop, produce and deliver a broad range of medicines needed by the US healthcare system to treat patients nationwide. Hikma has operated in the US since 1991 and has spent more than $4 billion over the past 15 years to build, enhance and expand its US-based R&D and manufacturing capabilities and now has annual domestic capacity to produce more than 12 billion finished doses of essential medicines. Over this period, Hikma has provided patients with access to a wide range of generic medicines at a lower cost than branded products. The company has an excellent record of US FDA quality inspections and has a successful record of working with FDA to solve critical drug shortages. Elected officials including US Rep. Mike Carey (OH-15) and US Rep. Buddy Carter (GA-01) joined Hikma at a special groundbreaking event held at the Company's state-of-the-art pharmaceutical manufacturing and R&D facility in Columbus, Ohio. America Leans on Hikma represents the Company's latest efforts to increase the volume of essential medicines it develops and produces across its R&D and manufacturing sites in Columbus and Cleveland, Ohio and in Cherry Hill and Dayton, New Jersey. This next phase of expansion will help to strengthen Hikma's portfolio of more than 800 medicines and increase the Company's US-based capacity to produce large volumes of high-quality and affordable medicines for American hospitals, providers and patients. "We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients," said Dr. Hafrun Fridriksdottir, President, Hikma Rx. "Hikma and our 2,300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines." Dr. Bill Larkins, President, Hikma Injectables added, "Over the past 15 years Hikma has grown to become a top three US supplier of sterile injectable medicines by volume with more than 180 injectable products in our portfolio and a growing pipeline. This new phase of US investment will enhance and expand our sterile injectables production capabilities and enable us to continue providing our broad portfolio of essential medicines to US patients." "As a pharmacist and Chairman of the American-Made Medicines Caucus, I understand the crucial role Hikma and other generic manufacturers play in delivering affordable and accessible medicines to Americans. It's important that we onshore the production of these critical drugs. I will continue working with Hikma to strengthen our national security and public health by making life-saving generic medications here, in America, and applaud them for their announcement today," said Rep. Buddy Carter. "Hikma continues to invest in American workers and I am thrilled that they have chosen to continue that commitment here in Columbus. This development will support a critical industry and create more jobs for working families in central Ohio. Additional manufacturing capacity will increase Americans' access to high-quality, affordable medicines. I am proud to join Hikma here today to support their mission and the Ohioans they employ. I look forward to returning to see the new facility once it is complete," Rep. Carey said. Hikma remains steadfast in its mission to provide affordable and accessible health care solutions. With this continued investment, Hikma reaffirms its commitment to ensuring a reliable supply of essential medications for all Americans. Contacts : Hikma Pharmaceuticals PLC Investors Susan Ringdal EVP, Strategic Planning and Global Affairs +44 (0)20 7399 2760/ +44 7776 477050 Media Steven Weiss US Communications +1 732 788 8279 About Hikma(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB/stable S&P and BBB/stable Fitch) Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: View original content to download multimedia: SOURCE Hikma Pharmaceuticals USA Inc.
